Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)

Merck (MRK) Shares Rally, Analyst Believes Data Supports Approval of Statercept in PAH

October 10, 2022 11:02 AM EDT

Merck (NYSE: MRK) announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept on Monday.

The company said the trial met its primary efficacy outcome measure, demonstrating a statistically significant and clinically meaningful improvement in the six-minute walk distance from baseline at 24 weeks.

Following the news, Mizuho analyst Mara Goldstein maintained a Buy rating and $100 per share price target on the stock, telling investors, "while specific details were not disclosed,... More

Merck (MRK) Climbs 1.6% After Upgrade, Phase 3 STELLAR Trial of Sotatercept Meets Primary Endpoint

October 10, 2022 7:22 AM EDT

Merck (NYSE: MRK) Climbs 1.6% After Upgrade, Phase 3 STELLAR Trial of Sotatercept Meets Primary Endpoint

Earlier Upgraded at GuggenheimPhase 3 STELLAR Trial of Sotatercept Meets Primary Endpoint... More